Acessibilidade / Reportar erro
Article • J. Braz. Chem. Soc. 30 (1) • Jan 2019 • https://doi.org/10.21577/0103-5053.20180146   copy

Synthesis and Cytotoxicity Evaluation of a Series of 3-Alkenyl-2-Hydroxy-1,4-Naphthoquinones Obtained by an Efficient Knoevenagel Condensation

Authorship SCIMAGO INSTITUTIONS RANKINGS

Abstract

A modified and efficient Knoevenagel condensation procedure was developed to synthesize the title compounds using β-alanine and acetic acid as catalysts, showing good to excellent yields. We used lawsone with suitable aliphatic aldehydes including isobutyraldehyde, 3-methyl-butyraldehyde, 2-ethylbutyraldehyde, phenylacetaldehyde, 2-phenyl-propionaldehyde, among others. These compounds were submitted to cytotoxic screening against three tumor cell lines presenting good to excellent cytotoxic profiles.

Keywords:
1,4-naphthoquinones; 3-alkenyl-2-hydroxy-1,4-naphthoquinones; lawsone; Knoevenagel condensation; cytotoxic evaluation

Introduction

The synthesis of 3-alkenyl-2-hydroxy-1,4-naphtho­quinones has been a topic of permanent interest in Brazil and abroad.11 Gomes, S. L. S.; Militão, G. C. G.; Costa, A. M.; Pessoa, C. O.; Costa-Lotufo, L. V.; Cunha-Junior, E. F.; Torres-Santos, E. C.; Costa, P. R. R.; da Silva, A. J. M.; J. Braz. Chem. Soc. 2017, 28, 1573.,22 de Oliveira, R. N.; da Silva, M. G.; da Silva, M. T.; Melo, V. N.; Valença, W. O.; da Paz, J. A.; Camara, C. A.; J. Braz. Chem. Soc. 2017, 28, 681. These compounds share structural features with natural lapachol (1), the most abundant quinone found in the core wood of various Bignoniaceae. Lapachol has a long tradition of use as a precursor of modified quinones, particularly for derivatives aimed at trials and screening of their multipurpose biological profiles.33 Brandão, G. C.; Missias, F. C. R.; Arantes, L. M.; Soares, L. F.; Roy, K. K.; Doerksen, R. J.; de Oliveira, A. B.; Pereira, G. R.; Eur. J. Med. Chem. 2018, 145, 191.

Hooker, in 1936,44 Hooker, S. C.; J. Am. Chem. Soc. 1936, 58, 1163. published a systematic synthetic procedure for a series of 3-alkenyl-2-hydroxy-1,4-naphtho­quinones using lawsone (2) with suitable aliphatic aldehydes with hydrochloric acid as catalyst. Hooker used propionaldehyde, n-butyraldehyde, valeraldehyde, heptanaldehyde, phenylacetaldehyde and hydrocynamaldehyde (3a-f), obtaining the corresponding products in low to modest yields (23-48%, Table 1). In this work, Hooker also pointed that he was unable to obtain the condensation product from isobutyraldehyde, and from acetaldehyde he notes that a rapid consumption of the formed product was observed.44 Hooker, S. C.; J. Am. Chem. Soc. 1936, 58, 1163. Fifty years later, in 1986, Bock et al.55 Bock, K.; Jacobsen, N.; Terem, B.; J. Chem. Soc., Perkin Trans. 1 1986, 659. published an update of this methodology (see Table 1).

Thumbnail
Table 1
Compounds 3a-l obtained by Hooker44 Hooker, S. C.; J. Am. Chem. Soc. 1936, 58, 1163. and Bock et al.55 Bock, K.; Jacobsen, N.; Terem, B.; J. Chem. Soc., Perkin Trans. 1 1986, 659.

Using (R)-(+)-citronelal (3 h) in Hooker's conditions, a cyclization to furnish only tetracyclic product 5 was observed (Scheme 1).55 Bock, K.; Jacobsen, N.; Terem, B.; J. Chem. Soc., Perkin Trans. 1 1986, 659. However, changing the catalytic conditions to basic triethylamine in more polar solvents as acetonitrile or dimethylformamide (DMF), the corresponding hydroxy-naphthoquinone (3h) was obtained with 20 and 28% yield, respectively.55 Bock, K.; Jacobsen, N.; Terem, B.; J. Chem. Soc., Perkin Trans. 1 1986, 659. These findings in the cyclization of lawsone with (R)-(+)-citronelal were also previously published by Ferreira et al.66 Ferreira, V. F.; Coutada, L. C.; Pinto, M. C. F. R.; Pinto, A. V.; Synth. Commun. 1982, 12, 195. in 1982.

Scheme 1
Tetracyclic quinone 5 from Hooker condensation using (R)-(+)-citronelal (3 h) by Ferreira et al.66 Ferreira, V. F.; Coutada, L. C.; Pinto, M. C. F. R.; Pinto, A. V.; Synth. Commun. 1982, 12, 195.

In the synthesis of tetracyclic vesparione in 1987, Kopanski et al.77 Kopanski, L.; Karbach, D.; Selbitschka, G.; Steglich, W.; Liebigs Ann. Chem. 1987, 793. developed a modified Knoevenagel procedure to obtain the deoxy-derivative of vesparione (6, Scheme 2) with 32% yield. The procedure involved a previously explored oxidative cyclization step using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in both acidic or basic media.88 Gilles, R. G. F.; Roos, G. H. P.; Tetrahedron Lett. 1975, 47, 4159.,99 Ameer, F.; Giles, R. G. F.; Green, I. R.; Pearce, R.; Synth. Commun. 2004, 34, 1247. The high yield of 2-cyclopentylidenemethyl-3-hydroxy-1,4-naphthoquinone (4m, 94%) was obtained by the use of β-alanine/acetic acid in benzene under reflux, using only two equivalent excess of aldehyde, compared with five equivalent or higher used by Hooker.44 Hooker, S. C.; J. Am. Chem. Soc. 1936, 58, 1163. Dehydropyranonaphthoquinones (6) could also be obtained using modified Knoevenagel procedure by one-pot condensation-cycloaddition using α,β-unsaturated aldehydes in the presence of ethylenediamine diacetate in moderate to good yields.1010 Lee, Y. R.; Choi, J. H.; Trinh, D. T. L.; Kim, N. W.; Synthesis 2005, 18, 3026.

Scheme 2
Two-step synthesis of 3,4-dehydropyrano-1,4-naphthoquinones using Knoevenagel conditions in the obtention of 2-hydroxy-3-alkenyl- 1,4‑naphthoquinone.77 Kopanski, L.; Karbach, D.; Selbitschka, G.; Steglich, W.; Liebigs Ann. Chem. 1987, 793.

Anufriev et al.,1111 Anufriev, V. F.; Chizhova, A. Y.; Denisenko, V. A.; Novikov, V. L.; Russ. J. Org. Chem. 1993, 29, 1671. in 1993, using a modified Hooker's methodology with methylamine hydrochloride in ethanol under reflux synthesized 3-alkenyl-2,5,8-trihydroxy-1,4-naphthoquinones (8) besides 3,3'-methylene-bisnaphthazarine (9) from naphthopurpurin (7, Table 2). Using few aliphatic aldehydes (propionaldehyde, isobutyraldehyde and valeraldehyde), they observed mixtures of 8 and 9 and using acetaldehyde or paraformaldehyde just dimers were formed. Using a similar approach in the selection of catalysts, Glazunov et al.,1212 Glazunov, V. P.; Berdyshev, D. V.; Yakubovskaya, A. Y.; Porkhilo, N. D.; Russ. J. Org. Chem. 2006, 55, 1729. in 2006, used methylamine hydrochloride and p-TsOH in refluxing benzene, obtaining modest yields of 2-hydroxy-3-alkenyl-1,4-naphthoquinones by the use of propanal (48%, conversion yield), 2-ethyl-butyraldehyde (44%) and using naphthopurpurine (7) with propanal (16%).

Thumbnail
Table 2
Condensation of 2-hydroxy-naphtharazin with selected aliphatic aldehydes yielding mixtures of expected alkenyls 8 and dimers 91111 Anufriev, V. F.; Chizhova, A. Y.; Denisenko, V. A.; Novikov, V. L.; Russ. J. Org. Chem. 1993, 29, 1671.

Using Bock's basic methodology,55 Bock, K.; Jacobsen, N.; Terem, B.; J. Chem. Soc., Perkin Trans. 1 1986, 659. Nagabhushana et al.,1313 Nagabhushana, K.; Ameer, F.; Green, I. R.; Synth. Commun. 2001, 31, 719. in 2001, studied the reaction conditions for the condensation products between caproaldehyde and lawsone with triethylamine as catalyst and also under some other different conditions. Using the optimized conditions they obtained a best result yield of 43% for the desired 2-hydroxy 3-(1'-hexenyl)-1,4-naphthoquinone.1313 Nagabhushana, K.; Ameer, F.; Green, I. R.; Synth. Commun. 2001, 31, 719.

As a part of a continuous interest of our laboratory in obtaining a range of 2-hydroxy-3-alkenyl-1,4-naphtho­quinones (4) from suitable aliphatic aldehydes and lawsone (2) under simple Knoevenagel conditions, we chose to perform a preliminary systematic study of experimental conditions to improve product yields, but also to find a general method to synthesize those interesting compounds. As pointed above, the use of modified Knoevenagel catalysts and water scavenger could reduce undesired reactions like lawsone dimerization and side chain acid cyclization, common side reactions in this type of condensation.1414 Pinheiro, S. M.; Silva, T. M. S.; Camara, C. A.; Br PI 10 2012 019793-6 A2 2015. Finally, the synthesized compounds were subjected to an evaluation screening for their potentials as antitumor lead compounds against different cancer cell lines. In this study, the biological screening also included a comparison with some other available furan and pyran derived hydroxymethyl-1,4-naphthoquinones obtained previously in our group by an acid catalyzed Prins cyclization of lapachol and norlapachol with paraformaldehyde and the newly corresponding acetyl derivatives.

Experimental

General information

Air- and moisture-sensitive reactions were carried out under argon atmosphere. Reagents were purchased from Sigma-Aldrich, Dinâmica or Vetec and distilled or used without further purification. Reactions were monitored by thin layer chromarography (TLC) analysis on precoated silica gel plates (Merck, Kieselgel 60 GF254) and compounds were visualized with UV light. Column chromatography was performed on silica gel 60 (70-230 mesh, Merck). Melting points were measured in open capillary tubes in a Quimis apparatus and are uncorrected. The infrared (IR) spectra were recorded on an IFS66 Bruker spectrophotometer using KBr discs or Varian Mercury 640IR with attenuated total reflectance (ATR). High resolution mass spectrometry (HRMS) analyses were performed on a matrix assisted laser desorption ionization-tandem time of flight (MALDI-TOF/TOF) Autoflex III 10, using positive reflected mode. Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Unity Plus-400 spectrometer (1H at 400 MHz and 13C at 100 MHz), 200 MHz Varian Mercury or Anasazi (90 MHz for 1H and 22.5 MHz for 13C), using CDCl3 or dimethyl sulfoxide-d6 (DMSO-d6) as solvents, and calibrated for the solvent signal. Chemical shifts are expressed in parts per million (ppm) and coupling constants are given in Hz. Assignments are based on correlation spectroscopy (COSY) and heteronuclear single quantum coherence (HSQC) experiments.

Synthesis

The compounds 10a (β-lapachone) and 10b (nor-β-lapachone) were obtained as described by literature methods from lapachol and norlapachol, respectively.1515 Silva Jr., E. N.; Souza, M. C.; Pinto, A. V.; Pinto, M. C.; Goulart, M. O.; Barros, F. W.; Pessoa, C.; Costa-Lotufo. L. V.; Montenegro, R. C.; Moraes, M. O.; Ferreira, V. F.; Bioorg. Med. Chem. 2007, 15, 7035.

Synthesis of 3-alkenyl-2-hydroxy-1,4-naphthoquinones compounds (4)

Method A: in a flask, it was added lawsone 2 (0.2 g, 1.2 mmol), β-alanine (0.03 g, 0.33 mmol) and toluene (40 mL), followed by glacial acetic acid (0.017 g, 0.28 mmol) and the corresponding aldehyde (2.3 mmol). The reaction system was kept under reflux using a Dean-Stark apparatus. The reaction was monitored by TLC for about 1 h. The solvent was removed and the compound was purified by crystallization in EtOH/H2O (4e, 4g, 4i, 4j) or by column chromatography with silica gel and hexanes:ethyl acetate 90:10 as eluent (4a, 4b, 4c, 4p).

Method B: in a flask, it was added lawsone (2, 0.2 g, 1.2 mmol), β-alanine (0.06 g, 0.67 mmol) and toluene (40 mL), followed by glacial acetic acid (0.034 g, 0.56 mmol) and the corresponding aldehyde (2.3 mmol). The reaction system was kept under reflux using Dean-Stark apparatus. Inspection of the progress of the reaction was made by TLC for about 1 h. The solvent was removed and the compound was purified by column chromatography with silica gel and hexanes:ethyl acetate 90:10 as eluent.

2-Hydroxy-3-propenyl-[1,4]naphthoquinone (C13H10O3) (4a)

Orange solid; mp 131-133 ºC (lit. 135.2-135.7 ºC);41H NMR (400 MHz, CDCl3) δ 8.11 (dd, 1H, J 7.8, 1.2 Hz), 8.05 (dd, 1H, J 7.4, 1.6 Hz), 7.74 (dt, 1H, J 7.8, 1.6 Hz), 7.67 (dt, 1H, J 7.8, 1.2 Hz), 7.07 (dq, 1H, J 16.0, 7.0 Hz), 6.62 (dq, 1H, J 16.0, 1.6 Hz), 1.98 (dd, 3H, J 7.0, 1.6 Hz); 13C NMR attached proton test (APT) (100 MHz, CDCl3) δ 184.2, 181.4, 151.2, 138.8, 134.8, 133.0, 132.7, 129.4, 127.0, 125.9, 119.9, 118.6, 20.5; IR (ATR) νmax / cm-1 3227, 2977, 1654, 1591, 1458, 1365, 1260; HRMS (MALDI) calcd.: 215.0703, found: 215.0713.

2-Hydroxy-3-butenyl-[1,4]naphthoquinone (C14H12O3) (4b)

Orange solid; mp 99 ºC (lit. 101.5 ºC);4 1H NMR (200 MHz, CDCl3) δ 8.09 (ddd, 1H, J 7.4, 1.4, 0.8 Hz), 8.05 (ddd, 1H, J 7.4, 1.4, 0.6 Hz), 7.81 (s, 1H), 7.80 (dt, 1H, J 7.4, 1.4 Hz), 7.70 (dt, 1H, J 7.6, 1.8 Hz), 7.30 (dt, 1H, J 16.2, 6.8 Hz), 6.70 (dt, 1H, J 16.2, 1.6 Hz), 2.29 (dq, 2H, J 7.2, 1.4 Hz), 1.19 (t, 3H, J 7.4 Hz); 13C NMR (APT) (50 MHz, CDCl3) δ 184.3, 181.3, 151.2, 145.4, 134.8, 133.0, 132.6, 129.4, 127.0, 125.9, 118.7, 117.7, 28.0, 13.3;1111 Anufriev, V. F.; Chizhova, A. Y.; Denisenko, V. A.; Novikov, V. L.; Russ. J. Org. Chem. 1993, 29, 1671. IR (KBr) νmax / cm-1 3330, 3072, 2964, 2933, 2876, 1652, 1592, 1459, 1372, 1341, 1263; HRMS (MALDI) calcd.: 229.0859, found: 229.0851.

2-Hydroxy-3-pentenyl-[1,4]naphthoquinone (C15H14O3) (4c)

Orange solid; mp 95-98 ºC (lit. 98-98.5 ºC);4 1H NMR (200 MHz, CDCl3) δ 8.08 (dd, 1H, J 7.2, 1.6 Hz), 8.01 (dd, 1H, J 7.4, 1.8 Hz), 7.70 (dt, 1H, J 7.6, 1.8 Hz), 7.66 (s, 1H), 7.62 (dt, 1H, J 7.4, 1.4 Hz), 7.03 (dt, 1H, J 16.2, 7.0 Hz), 6.57 (dt, 1H, J 16.4, 1.2 Hz), 2.24 (dq, 2H, J 7.2, 1.2 Hz), 1.49 (sex, 2H, J 7.2 Hz), 0.93 (t, 3H, J 7.4 Hz);1113C NMR (50 MHz, CDCl3) δ 184.3, 181.4, 151.2, 144.0, 134.8, 133.0, 132.6, 129.4, 127.0, 125.9, 118.8, 118.7, 37.1, 22.3, 13.8; IR (KBr) νmax / cm-1 3454, 3330, 2959, 2930, 2869, 1652, 1632, 1607, 1460, 1375, 1278; HRMS (MALDI) calcd.: 243.1016, found: 243.1001.

2-Hydroxy-3-styryl-[1,4]naphthoquinone (C18H12O3) (4e)

Orange crystals; mp 163-165 ºC (lit. 167-168 ºC);4 1H NMR (200 MHz, CDCl3) δ 8.13 (ddd, 1H, J 7.4, 1.6, 0.4 Hz), 8.04 (ddd, 1H, J 7.0, 1.4, 0.6 Hz), 7.93 (d, 1H, J 17 Hz), 7.73 (dt, 1H, J 7.2, 1.4 Hz), 7.65 (dt, 1H, J 7.2, 1.6 Hz), 7.57 (ddd, 2H, J 7.6, 1.6, 0.4 Hz), 7.36 (d, 1H, J 16.6 Hz), 7.36 (m, 3H); 13C NMR (APT) (50 MHz, CDCl3) δ 184.0, 180.9, 151.8, 139.1, 137.7, 134.8, 133.1, 132.6, 129.5, 128.6, 128.5, 127.1, 127.0, 125.9, 118.6, 117.3; IR (KBr) νmax / cm-1 3312, 3061, 3027, 2929, 1651, 1592, 1451, 1372, 1262; HRMS (MALDI) calcd.: 277.0859, found: 277.0857.

2-Hydroxy-3-(3-phenyl-propenyl)-[1,4]naphthoquinone (C19H14O3) (4f)

Orange crystals; mp 121-124 ºC (lit. 140.5-141.5 ºC);4 1H NMR (400 MHz, CDCl3) δ 8.11 (ddd, 1H, J 7.6, 7.1, 1.2, 0.5 Hz), 8.05 (ddd, 1H, J 7.3, 1.5, 0.5 Hz), 7.74 (dt, 1H, J 7.6, 1.4 Hz), 7.67 (ddt, 1H, J 7.6, 7.4, 1.2 Hz), 7.33-7.16 (m, 6H), 6.72 (dt, 1H, J 16.3, 1.5 Hz), 3.63 (dd, 2H, J 7.1, 1.2 Hz); 13C NMR (APT) (100 MHz, CDCl3) δ 184.1, 181.3, 151.5, 141.6, 139.6, 135.0, 133.1, 132.7, 129.4, 128.7, 128.5, 127.0, 126.3, 126.0, 119.8, 118.3, 41.3; IR (KBr) νmax / cm-1 3280, 3063, 2926, 2856, 1651, 1597, 1459, 1380, 1257; HRMS (MALDI) calcd.: 290.0937, found: 290.0956.

2-Hydroxy-3-(2-methyl-propenyl)-[1,4]naphthoquinone (C14H12O3) (4g)

Orange crystals; mp 114-117 ºC (lit. 119-120 ºC);16 1H NMR (200 MHz, DMSO-d6) δ 8.05-7.96 (m, 2H), 7.90-7.76 (m, 2H), 5.87 (m, 1H), 1.91 (d, 3H, J 1.2 Hz), 1.58 (d, 3H, J 0.8 Hz); 13C NMR (APT) (50 MHz, DMSO-d6) δ 185.2, 182.1, 155.0, 141.0, 135.5, 134.1, 133.0, 131.1, 126.8, 126.6, 121.5, 116.0, 27.0, 22.4; IR (KBr) νmax / cm-1 3363, 3074, 2969, 2927, 2863, 1647, 1592, 1453, 1377, 1275; HRMS (MALDI) calcd.: 229.0859, found: 229.0865.

2-Hydroxy-3-(3-methylbut-1-enyl)-[1,4]naphthoquinone (C15H14O3) (4i)

Red crystals; mp 107-110 ºC (lit. 118-119 ºC);1717 Oliveira, A. B.; Raslan, D. S.; Khuong-Huu, F.; Tetrahedron Lett. 1990, 31, 6873.1H NMR (200 MHz, CDCl3) δ 8.08 (ddd, 1H, J 7.2, 1.8, 0.8 Hz), 8.01 (dd, 1H, J 7.4, 1.4 Hz), 7.77 (s, 1H), 7.70 (dt, 1H, J 7.6, 1.8 Hz), 7.62 (dt, 1H, J 7.4, 1.4 Hz), 7.02 (dd, 1H, J 16.4, 7.2 Hz), 6.57 (dd, 1H, J 16.4, 1.2 Hz), 2.51 (m, 1H), 1.09 (d, 6H, J 6.6 Hz); 13C NMR (APT) (50 MHz, CDCl3) δ 184.3, 181.3, 151.2, 150.5, 134.9, 133.0, 132.7, 129.4, 127.0, 125.9, 118.7, 115.9, 33.4, 22.2;1111 Anufriev, V. F.; Chizhova, A. Y.; Denisenko, V. A.; Novikov, V. L.; Russ. J. Org. Chem. 1993, 29, 1671. IR (KBr) νmax / cm-1 3323, 2958, 2926, 2867, 1656, 1631, 1592, 1461, 1372, 1279; HRMS (MALDI) calcd.: 243.1016, found: 243.1030.

2-(2-Ethyl-but-1-enyl)-3-hydroxy-[1,4]naphthoquinone (C16H16O3) (4j)

Yellow crystals; mp 99-100 ºC (lit. 91-93 ºC);51H NMR (400 MHz, CDCl3) δ 8.12 (dd, 1H, J 7.6, 1.4 Hz), 8.09 (dd, 1H, J 7.6, 1.4 Hz), 7.75 (dt, 1H, J 7.6, 1.2 Hz), 7.69 (dt, 1H, J 7.6, 1.2 Hz), 7.48 (sl, 1H), 5.90 (s, 1H), 2.30 (dq, 2H, J 7.4, 1.4 Hz), 2.05 (q, 2H, J 7.4 Hz), 1.16 (t, 3H, J 7.4 Hz), 1.01 (t, 3H, J 7.6 Hz); 13C NMR (APT) (100 MHz, CDCl3) δ 184.7, 181.5, 153.6, 151.4, 134.9, 133.0, 132.9, 129.5, 126.9, 126.0, 121.2, 111.1, 28.9, 26.4, 12.6, 12.1; IR (KBr) νmax / cm-1 3439, 2965, 2935, 2876, 1663, 1643, 1593, 1459, 1332, 1273; HRMS (MALDI) calcd.: 257.1172, found: 257.1181.

2-Hydroxy-3-hexenyl-[1,4]naphthoquinone (C16H16O3) (4p)

Orange solid; mp 83-85 ºC (lit. 82-83 ºC);4 1H NMR (90 MHz, CDCl3) δ 8.09 (dd, 1H, J 6.9, 2.2 Hz), 8.02 (dd, 1H, J 6.9, 2.2 Hz), 7.82-7.53 (m, 2H), 7.08 (dt, 1H, J 16.4, 6.9 Hz), 6.58 (dt, 1H, J 16.1, 1.1 Hz), 2.30 (dq, 2H, J 6.6, 1.1, 0.7 Hz), 1.64-1.18 (m, 4H), 1.00-0.84 (m, 3H, J 6.6 Hz); 13C NMR (22.73 MHz, CDCl3) d 184.7, 181.9, 151.8, 144.6, 135.3, 133.4, 127.5, 126.4, 119.2, 35.2, 31.7, 22.9, 14.4; IR (KBr) νmax / cm-1 3449, 3268, 2959, 2927, 2858, 1654, 1632, 1608, 1593, 1458, 1371, 1265; HRMS (MALDI) calcd.: 257.1172, found: 257.1188.

2-Hydroxy-3-(2-phenyl-propenyl)-[1,4]naphthoquinone (C19H14O3) (4q)

Orange crystals; mp 142-144 ºC (lit. 141.2-143.6 ºC);1818 Wang, N.; Wu, X.; Qin, T.; Zhou, J.; You, Q.; Zhang, X.; RSC Adv. 2016, 6, 104126.1H NMR (400 MHz, CDCl3) δ 8.15 (dd, 1H, J 7.6, 1.4 Hz), 8.11 (dd, 1H, J 7.6, 1.5 Hz), 7.77 (ddt, 1H, J 7.6, 1.5, 0.7 Hz), 7.70 (ddt, 1H, J 7.6, 1.5, 0.7 Hz), 7.58 (m, 2H), 7.38-7.27 (m, 3H), 6.62 (m, 1H), 2.08 (m, 3H); 13C NMR (APT) (100 MHz, CDCl3) δ 184.5, 181.4, 151.3, 144.1, 142.5, 135.0, 133.1, 133.0, 129.6, 128.3, 127.8, 127.0, 126.2, 126.2, 120.8, 116.0, 19.5; IR (KBr) νmax / cm-1 3374, 3081, 2957, 2929, 2859, 1664, 1638, 1595, 1459, 1326, 1276, 1255; HRMS (MALDI) calcd.: 290.0937, found: 290.0933.

2-Cyclopent-1-enyl-3-hydroxy-[1,4]naphthoquinone (C15H12O3) (4r)

Orange crystals; mp 111-113 ºC; 1H NMR (400 MHz, CDCl3) δ 8.10 (ddd, 1H, J 7.8, 1.2, 0.8 Hz), 8.05 (ddd, 1H, J 7.8, 1.2, 0.8 Hz), 7.73 (ddt, 1H, J 7.8, 1.6, 0.8 Hz), 7.65 (ddt, 1H, J 7.4, 1.6, 0.8 Hz), 6.53 (m, 1H), 2.85 (ddd, 1H, J 7.4, 4.3, 2.0 Hz), 2.83 (ddd, 1H, J 7.4, 4.3, 2.0 Hz), 2.55 (ddd, 1H, J 7.0, 4.7, 2.4 Hz), 2.53 (ddd, 1H, J 7.0, 4.7, 2.4 Hz), 1.94 (qui, 2H, J 7.8, 7.4 Hz); 13C NMR (APT) (100 MHz, CDCl3) δ 184.1, 181.5, 151.7, 138.9, 134.9, 133.7, 133.2, 132.8, 129.1, 127.0, 125.8, 119.7, 35.6, 33.6, 23.4; IR (KBr) νmax / cm-1 3325, 3081, 2962, 2930, 2873, 1651, 1591, 1461, 1365, 1245; HRMS (MALDI) calcd.: 240.0781, found: 240.0780.

Synthesis of 10b and 11b

In a preheated flask filled with formic acid (25 mL), it was added paraformaldehyde (1.32 g, 44.3 mmol) followed by corresponding lapachol or norlapachol (22 mmol). The reaction was heated for 2 h at 90 ºC, and water (50 mL) was added and the mixture was kept under reflux for 12 h. The reaction mixture was cooled, neutralized with Na2CO3 saturated solution and the resulting precipitate was submitted to vacuum filtration. The compounds were purified by column chromatography with silica gel using mixtures of dichlorometane:hexanes and dichloromethane:ethyl acetate with increasing polarity.

3-Hydroxymethyl-2,2-dimethyl-3,4-dihydro-2H-benzo [h]chromene-5,6-dione (C16H16O4) (10b)

Orange crystals (51%); mp 147-150 ºC; 1H NMR (200 MHz, CDCl3) d 7.96 (dd, 1H, J 7.6, 1.2 Hz), 7.74 (dd, 1H, J 7.6, 1.0 Hz), 7.59 (ddd, 1H, J 8, 7.6 Hz), 7.67 (dd, 1H, J 8, 7.6 Hz), 3.82 (dd, 1H, J 11, 5.2 Hz), 3.60 (dd, 1H, J 7, 11 Hz), 3.01 (br, 1H), 2.74 (dd, 1H, J 5.6, 17.6 Hz), 2.27 (dd, 1H, J 17.6, 11 Hz), 2.01 (m, 1H, J 5.2, 5.6, 7, 11 Hz), 1.56 (s, 3H), 1.30 (s, 3H); 13C NMR (APT) (50.3 MHz, CDCl3) δ 179.7, 178.4, 161.9, 134.8, 132.1, 130.7, 129.9, 128.4, 124.1, 112.4, 81.7, 71.0, 62.6, 27.5, 21.9, 19.6; IR (KBr) νmax / cm-1 3072, 2982, 1737, 1695, 1607, 1572, 1457, 1392, 1293, 1232, 1132, 1092, 1034, 984, 934; HRMS (MALDI) calcd.: 273.1121, found: 273.1119.

3-Hydroxymethyl-2,2-dimethyl-2,3-dihydro-naphtho [1,2-b]furan-4,5-dione (C15H14O4) (11b)

Dark red crystals (76%); mp 122-124 ºC; 1H NMR (400 MHz, CDCl3) δ 8.03 (d, 1H, J 7.5 Hz), 7.66 (m, 2H), 7.58 (m, 1H), 4.03 (sl, 1H), 3.85 (dd, 1H, J 11, 8.4 Hz), 3.78 (dd, 1H, J 11, 4.3 Hz), 3.35 (dd, 1H, J 8.3, 4.6 Hz), 1.65 (s, 3H), 1.47 (s, 3H); 13C NMR (APT) (100 MHz, CDCl3) δ 181.0, 176.4, 170.5, 134.6, 132.4, 130.7, 129.2, 127.3, 124.9, 117.4, 95.4, 61.3, 52.4, 29.1, 22.2; IR (KBr) νmax / cm-1 3362, 2968, 2926, 1645, 1591, 1456, 1376, 1343, 1275, 1213, 1163; HRMS (MALDI) calcd.: 259.0965, found: 259.0961.

Synthesis of 10c and 11c

In a round bottom flask with 10a or 11a (200 mg), it was added acetic anhydride (1 mL, 10.6 mmol) followed by pyridine (1 mL, 12.4 mmol). After 2.5 h, after TLC inspection, the product was precipitated in ice-water and submitted to vacuum filtration and column chromatography with silica gel using mixtures of dichlorometane:hexanes and dichloromethane:ethyl acetate with increasing polarity.

3-[(Acetyloxy)methyl]-2,2-dimethyl-3,4-dihydro-2H-benzo [h]chromene-5,6-dione (C18H18O5) (10c)

Purified by chromatography using silica gel with hexanes:ethyl acetate 6:4 yielding an yellow solid (54%); mp 91-92 ºC; 1H NMR (400 MHz, CDCl3) δ 7.97 (dd, 1H, J 7.8, 1.6 Hz), 7.73 (dd, 1H, J 7.8, 1.6 Hz), 7.59 (dt, 1H, J 7.8, 1.6 Hz), 7.45 (dt, 1H, J 7.4, 1.2 Hz), 4.23 (dd, 1H, J 11.4, 5.1 Hz), 3.88 (dd, 1H, J 11.3, 7.4 Hz), 2.74 (dd, 1H, J 17.6, 5.4 Hz), 2.28 (dd, 1H, J 17.6, 9.4 Hz), 2.15 (m, 1H), 2.02 (s, 3H), 1.54 (s, 3H), 1.32 (s, 3H); 13C NMR (APT) (100 MHz, CDCl3) δ 179.3, 178.2, 170.6, 134.7, 130.7, 129.9, 128.4, 124.0, 111.8, 80.6, 64.0, 39.2, 27.2, 21.9, 20.7, 19.8; IR (KBr) νmax / cm-1 3068, 2975, 1714, 1643, 1614, 1587, 1488, 1403, 1334, 1275, 1177, 1107, 1076; HRMS (MALDI) calcd.: 315.1227, found: 315.1229.

3-[(Acetyloxy)methyl]-2,2-dimethyl-2,3-dihydro-naphtho [1,2-b]furan-4,5-dione (C17H16O5) (11c)

Purified by recristallization from EtOH/H2O yielding brownish crystals (86%); mp 140-141 ºC; 1H NMR (400 MHz, CDCl3) δ 8.08 (d, 1H, J 7.2 Hz), 7.61 (m, 3H), 4.51 (dd, 1H, J 11.2, 4.0 Hz), 4.24 (dd, 1H, J 11.6, 9.2 Hz), 3.49 (dd, 1H, J 9.2, 4.0 Hz), 2.04 (s, 3H), 1.59 (s, 3H), 1.58 (s, 3H); 13C NMR (APT) (100 MHz, CDCl3) δ 180.9, 175.4, 170.5, 169.0, 134.5, 132.2, 130.9, 129.4, 127.5, 124.8, 114.3, 94.7, 61.5, 47.9, 29.6, 22.2, 20.8; IR (KBr) νmax / cm-1 2099, 2901, 1734, 1695, 1611, 1567, 1490, 1402, 1379, 1243, 1120, 1082; HRMS (MALDI) calcd.: 301.1071, found: 301.1074.

In vitro citotoxicity assay

The human lung carcinoma cell line (NCI-H292), human larynx carcinoma cell line (HEP-2) and breast adenocarcinoma (MCF-7) were purchased from the Adolfo Lutz Institute, São Paulo, Brazil. A Dulbecco's Modified Eagle's medium (DMEM), enriched with 10% of fetal bovine serum, 1% of L-glutamine and 1% of antibiotics (penicillin and streptomycin), was used for cell cultivation and to perform the tests. The cytotoxic activity was investigated using the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.1919 Alley, M. C.; Scudiero, D. A.; Monsk, A.; Hursey, M. I.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R.; Cancer Res. 1988, 48, 589. Cell suspensions were diluted to 105 cells mL-1, suitably prepared and distributed in plates of culture with 96 wells (225 µL in each well), then incubated at 37 ºC in a humid atmosphere with 5% of CO2. After 24 h, 25 µL of either the synthesized compounds or the reference drugs (doxorubicine and cisplatin) were added to each well. The plates were incubated again at 37 ºC for 72 h. Then, 25 µL of MTT solution (5 mg mL-1) were added to each well, and the mixture was incubated at 37 ºC for 2 h. At the end of this period, the culture medium with the MTT excess was aspirated and after that, 100 µL of DMSO were added to each well to dissolve the formazan crystals.2020 Mosmann, T.; J. Immunol. Methods 1983, 16, 55. The optical density (OD) of the wells was measured at 540 nm and compared to the control (cells with medium only). The data represent the mean of two experiments in triplicate and were expressed as means ± standard deviation (SD).2121 Berridge, M. V.; Tan, A. S.; McCoy, K. D.; Wang, R.; Biochemica 1996, 4, 14. The concentration at which 50% survival of cells was observed (IC50), the effective concentration causing 50% decrease in cell viability (EC50) and their 95% confidence intervals were determined from nonlinear regression using the program SigmaPlot version 11.2222 Systat Software; SigmaPlot version 11; Systat Software, San Jose, CA, USA, 2008.

Results and Discussion

The preliminary data found by the present method in the synthesis of norlapachol 4g showed a 95% yield, and resulted in patent filing.1414 Pinheiro, S. M.; Silva, T. M. S.; Camara, C. A.; Br PI 10 2012 019793-6 A2 2015. In this method, benzene was substituted by toluene, a greener and safer solvent with a higher boiling point. As far as we know, this remarkable result is better than any previously reported in the literature. For example, the classic Hooker's oxidative degradation of natural lapachol 1 to obtain norlapachol 4g results in yields around 50%.1616 Fieser, L. F.; Fieser, M.; J. Am. Chem. Soc. 1948, 70, 3215. Initially, we planned to use the inexpensive n-butyraldehyde as a model to observe the importance of some reaction conditions employed in original Kopanski methodology (Table 3), in particular the proportion of acetic acid/β-alanine catalyst, the amount of aldehyde, the substitution of acetic acid by p-TsOH, and the substitution of β-alanine by triethylamine or L-proline (Table 3).

Thumbnail
Table 3
Variation in conditions for the condensation of lawsone 2 with n-butyraldehyde

From the data of Table 3, we conclude that the acetic acid or β-alanine alone were not effective as catalysts (entries 1 and 2), but the use of the mixture (entry 3) results in a good yield of 64%. Increase of acid alone or β-alanine, however (entries 4 and 5, respectively), did not contribute to further increase the observed yields. An increase of two-fold in the aldehyde drops the yield (entry 6), probably caused by competition for self-condensation; however, the increase of catalyst in a 4:1:1 proportion of aldehyde:acetic acid:β-alanine results in the best yield of 81% (entry 7). Increasing two-fold the proportion of either catalyst or both (entries 8, 9 and 10) drops the observed yield. Changing the acetic acid by triethylamine or p-toluenesulfonic acid (entries 11 and 12) also drops the yield. The use of a known condensation catalyst L-proline (entry 13) was also unsuccesful. The reaction seems to be sensitive to the amount of acid and β-alanine, however, all the reactions with excess acid catalysis results in the formation of the bis-adduct dimer of lawsone, a polar product visible by TLC inspection that was studied in a previous article by our group.2323 Araújo, M. V.; Souza, P. S. O.; Queiroz, A. C.; Matta, C. B. B.; Leite, A. B.; Silva, A. E.; França, J. A. A.; Silva, T. M. S.; Camara, C. A.; Alexandre-Moreira, M. S.; Molecules 2014, 19, 15180. We chose to compare this modification of the original Kopanski procedure (named method A, entry 3), with this new method B (entry 9, Table 3) in a series of experiments conducted to verify the scope of the method with a range of suitable aldehydes. These results are shown in Table 4, and we planned to submit initially the available propionaldehyde (3a), n-butyraldehyde (3b), n-valeraldehyde (3c), phenylacetaldehyde (3e), n-hexanaldehyde (3p), isobutyraldehyde (3g), isovaleraldehyde (3i) and 2-ethylbutyraldehyde (3j) to condense with lawsone (2) using both conditions A and B that differ only by B using twice the amount of catalyst that A uses (Table 4). The best yields were obtained in either method for the more substituted alkyl, specially those with an extra alkyl at alpha position (see entries 6-8). This should reflect an easier elimination step at the formation of a more stable substituted double bond. This effect could be extended to the stabilization of the double bond by conjugation with a phenyl group (entry 4). The use of twice the amount of catalyst in method B should give better and more consistent yields without exceptions.

Thumbnail
Table 4
Knoevenagel condensation reaction conditions and yields using methods A and B with suitable aldehydes

At a glance we could see that method B was generally better than the previous one, varying from an excelent yield of 95 and 96% for phenylaceltadehyde (3e) and 2-ethylbutyraldehyde (3j) (entries 4 and 8), respectively, to good yields (85, 86 and 85%) for isobutyraldehyde (3g), isovaleraldehyde (3i) and 2-phenyl-propionaldehyde (3q) (entries 6, 7 and 10), respectively. Linear alkyl aldehydes are also otained in good yields of 70 and 76%, respectively, for n-valeraldehyde (3c) and n-hexanaldehyde (3p) (entries 3 and 9), representing better yields than those afforded using method A. The 3-phenyl-propionaldehyde (3f) and even the cyclopentanone (3r) furnish modest yields of 47 and 36% (entries 5 and 11, Table 4), respectively, using method B. These last two precursors and 2-phenyl-propionaldehyde (3q) did not react (entries 5, 10 and 11) at the conditions used in method A by TLC inspection. However, the method did not improve the yield of propionaldehyde (3a), entry 1. With the aid of some minor condition modifications, as the use of β-alanine alone as catalyst with 2 h reaction time, we are able to improve almost twice the yield of 3a to 31%. We believe that the extremely low boiling point of propionaldehyde could explain the observed low yield. The compound 2-phenyl-propionaldehyde (3q) was only recently described and synthesized by the aid of a Pd-catalyzed hydroxy-involved enolate-type reaction with lawsone and suitable alkenes. Previously, this type of functionalization of a 2-hydroxy-naphthoquinone used labor-intensive alkylation conditions2424 Fiorito, S.; Epifano, F.; Bruyere, C.; Mathieu, V.; Kiss, R.; Genovese, S.; Bioorg. Med. Chem. Lett. 2014, 24, 454. or phenyliodonium ylides BF3 catalyzed cross coupling.2525 Malamidou-Xenikaki, E.; Tsanakopoulou, M.; Chatzistefanou, M.; Litina, D. H.; Tetrahedron 2015, 71, 5650. Although Knoevenagel condensations with acyclic or cyclic ketones as enolates are common,2626 Chinchkar, S. M.; Patil, J. D.: Korade, S. N.; Gokavi, G. S.; Shejawal, R. V.; Pore, D. M.; Lett. Org. Chem. 2017, 14, 403. it is noteworthy that in our report the cyclopentanone yielding compound 4r was used almost always as an electrophile,2727 Ce, S.; Zhen-Chu, C.; Qin-Guo, Z.; Synthesis 2003, 555. and as far as we know, this compound is new. The similar reaction with cyclohexanone gives no results with the sort of different modifications described before in this work.

The synthesis of the furan (10b) and pyran (11b) 3-hydroxymethyl-1,4-naphthoquinones were performed by the reaction of lapachol 1 or norlapachol 4g with paraformaldehyde in formic acid (Scheme 3), resulting in the condensation of the alkene quinone side chain and the formaldehyde by a Prins reaction,2828 Camara, C. A.; Pinto, A. C.; Vargas, M. D.; Zukerman-Schpector, J.; Tetrahedron 2002, 58, 6135.,2929 Barbosa, T. P.; Camara, C. A.; Silva, T. M. S.; Martins, R. M.; Pinto, A. C.; Vargas, M. D.; Biorg. Med. Chem. Lett. 2005, 13, 6464. followed by in situ cyclization, in 76 and 51% yield, respectively. The corresponding acetates 10c and 11c were obtained by straightforward acetylation procedure in 86 and 54% yield, respectively.

Scheme 3
The synthesis of the furan (10b) and pyran 3-hydroxymethyl-1,4-naphthoquinones (11b) and corresponding acetates 10c and 11c from lapachol (1) and norlapachol 4g.

Concerning the biological activity, the title compounds 4e, 4i, 4j, and 4p were previously tested together for antifungal activity,3030 Jacobsen, N.; Wengel, A.; Pestic. Sci. 1986, 17, 686.4g and 4i for molluscicidal activity,3131 Santos, A. F.; Ferraz, P. A. L.; Pinto, A. V.; Pinto, M. C. F. R.; Goulart, M. O. F.; Sant'Ana, A. E. G.; Int. J. Parasitol. 2000, 30, 1199.,3232 Lima, N. M. F.; Santos, A. F.; Porfírio, Z.; Goulart, A. O. F.; Sant'Ana, A. E. G.; Acta Trop. 2002, 83, 43.4g for antimycobacterial activity,3333 Carneiro, P. F.; Pinto, M. C. F. R.; Coelho, T. S.; Cavalcanti, B. C.; Pessoa, C.; de Simone, C. A.; Nunes, I. K. C.; de Oliveira, N. M.; de Almeida, R. G.; Pinto, A. V.; de Moura, K. C. G.; da Silva, P. A.; da Silva Jr., E. N.; Eur. J. Med. Chem. 2011, 46, 4521.4b, 4g and 4i for trypanocidal activity,3434 Souza, N. B.; Andrade, I. M.; Carneiro, P. F.; Jardim, G. A. M.; Melo, I. M. M.; Silva, E. N.; Krettli, A. U.; Mem. Inst. Oswaldo Cruz 2014, 109, 546.4g and 4i for leishmanicial activity,3535 Guimarães, T. T.; Pinto, M. C. F. R.; Lanza, J. S.; Melo, M. N.; Monte-Neto, R. L.; Melo, I. M. M.; Diogo, E. B. T.; Ferreira, V. F.; Camara, C. A.; Valença, W. O.; Oliveira, R. N.; Frézard, F.; Silva Jr., E. N.; Eur. J. Med. Chem. 2013, 63, 523.,3636 Lima, N. M. F.; Correia, C. S.; Leon, L. L.; Machado, G. M. C.; Madeira, M. F.; Santana, A. E. G.; Goulart, M. O. F.; Mem. Inst. Oswaldo Cruz 2004, 99, 757. and 4e was evaluated for cytotoxicity,3737 Cushion, M. T.; Chen, F.; Kloepfer, N.; Antimicrob. Agents Chemother. 1997, 41, 379. antifungal3030 Jacobsen, N.; Wengel, A.; Pestic. Sci. 1986, 17, 686. and anticancer activities.2424 Fiorito, S.; Epifano, F.; Bruyere, C.; Mathieu, V.; Kiss, R.; Genovese, S.; Bioorg. Med. Chem. Lett. 2014, 24, 454. Although the majority of the title compounds were known and tested elsewhere, they were all tested together in the present study for cytotoxic screening against tumor cell lines HEP-2, MCF-7 and NCI-H292 (Table 5).

Thumbnail
Table 5
Cell growth inhibition percentual of the 3-alkenyl-2-hydroxy-1,4‑naphthoquinones (4) and cyclic derivatives 10a-c and 11a-c at 25 µg mL-1 in the three tumor cell lines

Concerning the inhibition of growth of HEP-2 tumor cells, the compounds alkenyl-1,4-naphthoquinone series 4b, 4c, 4i, 4j, 4p and 4q showed the highest percentuals of inhibition, superior to those from lapachol 1 and reference compound doxorubicin (Table 5). Compound 4c showed a higher percentual of inhibition (95.6%) against (HEP-2) cell lines when compared to 4j with 94.1%, 4p with 94%, 4b with 93.5%, 4i with 93% and 4q with 91.2%. In this series the norlapachol 4g showed the lowest inhibition percentual (27.3%) (Table 5). Concerning the MCF-7 cell line tested the only compound with high activity was 4j with 77.9% inhibition, showing a better profile than the isomer with a linear alkyl side chain 4p with 53.6% inibition (Table 5). Notably, in these experimental trials the compound norlapachol 4g did not inhibit the growth of MCF-7 cells or of NCI-H292. In NCI-H292, the highest inhibition for the alkenyl-1,4-naphthoquinones 4 were 85.9, 85.7 and 85.3% for compounds 4i, 4j and 4r, respectively (Table 5). The presence of an additional phenyl ring in compounds 4e, 4f and 4q did not improve the biological profile. From the data on Table 5 we could see that the series of alkenyl-1,4-naphthoquinones 4 showed a remarkable selectivity to the larynx tumor cell lines, when compared to other tumor cell lines.

A very different scenario is obtained when the cyclized derivatives 10a-c and 11a-c were compared with the open chain alkenyl 1,4-naphthoquinones 4, with all compounds showing excellent profiles of inhibition, ranging from 99% for 10c in HEP-2 cell lines to 92.7% for 11c in NCI-H292 cell lines. The acetylation of the hydroxymethyl groups enhances the observed activities in all tested cell lines, either in pyran 10b or furan 11b series (Table 5).

In order to determine the half maximal inhibitory concentration (IC50) values (µM) displayed in Table 6, we decided to adopt a threshold for using only compounds with at least 75% inhibition in all cell lines tested (at 25 mg mL-1 concentration). Thus, compounds 4j, 10a-c and 11a-c are those satisfying this criterion as can be observed from the data in Table 5. The 3-alkenyl-2-hydroxy-1,4-naphthoquinone compound 4j was shown to be the least cytotoxic for all tested cell lines (Table 6). For the MCF-7 tumor cell line, compounds 11a-c were more active than 10a-c, β-nor-lapachone (11a) being more cytotoxic than 11b, 11c, and even more cytotoxic than the positive control. All tested cyclized compounds showed a remarkable citotoxic profile against the breast MCF-7 tumor cell line, ranging from 0.10 µM for 11a to 5.51 µM for 10b. Also in this tumor cell line, the hydroxymethyl 10b/11b and acetate derivatives 10c/11c resulted in decreased cytotoxicity when compared to the parent compounds β-lapachone (10) and β-nor-lapachone (11), although 10c did not result in changes to the observed activity (Table 6). The tumor cell lines NCI-H292 and HEP-2 showed more sensitivity to the acetylated derivative 10c, with IC50 of 2.26 and 6.81 µM, respectively, and also for the less active 11c, with IC50 values of 11.13 and 13.6 µM, respectively. In general, the tested compounds showed remarkable and consistent cytotoxicity in tested cancer cell lines, although the compounds presented high inhibitory effect in the growth of Buffalo green monkey kidney (BGMK) cells used to access the selectivity, which means a non-selective effect and high cytoxicity for the series tested, except for the series of cyclic furan-1,4-naphthoquinone and 3-hydroxymethyl derivatives 11a-c, which showed a good selectivity index for MCF-7.

Thumbnail
Table 6
Cytotoxic activity expressed as IC50 of compounds 4j, 10a-c and 11a-c against tumor cell lines

Conclusions

In this work a very efficient Knoevenagel procedure was presented for the obtention of 2-hydroxy-3-alkenyl-1,4-naphthoquinones (4) from lawsone (2) and suitable aldehydes, using β-alanine and acetic acid as catalysts. The method runs with overall good yields in a systematic fashion. Some of the parameters briefly studied here could be easily altered resulting in improved reaction yields, especially when using non-linear chain aldehydes. We also presented the synthesis of a series of furan and pyran-derived hydroxymethyl-1,4-naphthoquinones obtained by an acid catalyzed Prins cyclization of lapachol and norlapachol and corresponding acetyl derivatives. The 2-hydroxy-3-alkenyl-1,4-naphthoquinone (4) series was in general less cytotoxic than the cyclized furan- and pyran-naphthoquinones 10/11. The β-nor-lapachone (11a) was the most active compound in the MCF-7 tumor cell line. In general, the furan- (β-nor-lapachone) (11) derivatives were more active than pyran-β-lapachone (10), and the presence of the hydroxyl and acetate groups decreased the cytotoxicity of β-lapachone and β-nor-lapachone. Also the 2-(2-ethyl-but-1-enyl)-3-hydroxy-[1,4]naphthoquinone (4j) was shown to be the less cytotoxic for all tumor cell lines tested.

  • Supplementary Information
    Supplementary information is available free of charge at http://jbcs.sbq.org.br as PDF file.

Acknowledgments

The authors thank CAPES, CNPq and FACEPE (PRONEM APQ 0741.11.06/14) for financial support, and the Central Analítica of DQF-UFPE and CENAPESQ-UFRPE for the use of facilities. C. A. C. thanks Eduardo J. Oliveira (UFVJM) for useful suggestions.

References

  • 1
    Gomes, S. L. S.; Militão, G. C. G.; Costa, A. M.; Pessoa, C. O.; Costa-Lotufo, L. V.; Cunha-Junior, E. F.; Torres-Santos, E. C.; Costa, P. R. R.; da Silva, A. J. M.; J. Braz. Chem. Soc 2017, 28, 1573.
  • 2
    de Oliveira, R. N.; da Silva, M. G.; da Silva, M. T.; Melo, V. N.; Valença, W. O.; da Paz, J. A.; Camara, C. A.; J. Braz. Chem. Soc 2017, 28, 681.
  • 3
    Brandão, G. C.; Missias, F. C. R.; Arantes, L. M.; Soares, L. F.; Roy, K. K.; Doerksen, R. J.; de Oliveira, A. B.; Pereira, G. R.; Eur. J. Med. Chem 2018, 145, 191.
  • 4
    Hooker, S. C.; J. Am. Chem. Soc 1936, 58, 1163.
  • 5
    Bock, K.; Jacobsen, N.; Terem, B.; J. Chem. Soc., Perkin Trans. 1 1986, 659.
  • 6
    Ferreira, V. F.; Coutada, L. C.; Pinto, M. C. F. R.; Pinto, A. V.; Synth. Commun 1982, 12, 195.
  • 7
    Kopanski, L.; Karbach, D.; Selbitschka, G.; Steglich, W.; Liebigs Ann. Chem 1987, 793.
  • 8
    Gilles, R. G. F.; Roos, G. H. P.; Tetrahedron Lett. 1975, 47, 4159.
  • 9
    Ameer, F.; Giles, R. G. F.; Green, I. R.; Pearce, R.; Synth. Commun 2004, 34, 1247.
  • 10
    Lee, Y. R.; Choi, J. H.; Trinh, D. T. L.; Kim, N. W.; Synthesis 2005, 18, 3026.
  • 11
    Anufriev, V. F.; Chizhova, A. Y.; Denisenko, V. A.; Novikov, V. L.; Russ. J. Org. Chem 1993, 29, 1671.
  • 12
    Glazunov, V. P.; Berdyshev, D. V.; Yakubovskaya, A. Y.; Porkhilo, N. D.; Russ. J. Org. Chem 2006, 55, 1729.
  • 13
    Nagabhushana, K.; Ameer, F.; Green, I. R.; Synth. Commun 2001, 31, 719.
  • 14
    Pinheiro, S. M.; Silva, T. M. S.; Camara, C. A.; Br PI 10 2012 019793-6 A2 2015
  • 15
    Silva Jr., E. N.; Souza, M. C.; Pinto, A. V.; Pinto, M. C.; Goulart, M. O.; Barros, F. W.; Pessoa, C.; Costa-Lotufo. L. V.; Montenegro, R. C.; Moraes, M. O.; Ferreira, V. F.; Bioorg. Med. Chem. 2007, 15, 7035.
  • 16
    Fieser, L. F.; Fieser, M.; J. Am. Chem. Soc. 1948, 70, 3215.
  • 17
    Oliveira, A. B.; Raslan, D. S.; Khuong-Huu, F.; Tetrahedron Lett. 1990, 31, 6873.
  • 18
    Wang, N.; Wu, X.; Qin, T.; Zhou, J.; You, Q.; Zhang, X.; RSC Adv. 2016, 6, 104126.
  • 19
    Alley, M. C.; Scudiero, D. A.; Monsk, A.; Hursey, M. I.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R.; Cancer Res 1988, 48, 589.
  • 20
    Mosmann, T.; J. Immunol. Methods 1983, 16, 55.
  • 21
    Berridge, M. V.; Tan, A. S.; McCoy, K. D.; Wang, R.; Biochemica 1996, 4, 14.
  • 22
    Systat Software; SigmaPlot version 11; Systat Software, San Jose, CA, USA, 2008.
  • 23
    Araújo, M. V.; Souza, P. S. O.; Queiroz, A. C.; Matta, C. B. B.; Leite, A. B.; Silva, A. E.; França, J. A. A.; Silva, T. M. S.; Camara, C. A.; Alexandre-Moreira, M. S.; Molecules 2014, 19, 15180.
  • 24
    Fiorito, S.; Epifano, F.; Bruyere, C.; Mathieu, V.; Kiss, R.; Genovese, S.; Bioorg. Med. Chem. Lett 2014, 24, 454.
  • 25
    Malamidou-Xenikaki, E.; Tsanakopoulou, M.; Chatzistefanou, M.; Litina, D. H.; Tetrahedron 2015, 71, 5650.
  • 26
    Chinchkar, S. M.; Patil, J. D.: Korade, S. N.; Gokavi, G. S.; Shejawal, R. V.; Pore, D. M.; Lett. Org. Chem 2017, 14, 403.
  • 27
    Ce, S.; Zhen-Chu, C.; Qin-Guo, Z.; Synthesis 2003, 555.
  • 28
    Camara, C. A.; Pinto, A. C.; Vargas, M. D.; Zukerman-Schpector, J.; Tetrahedron 2002, 58, 6135.
  • 29
    Barbosa, T. P.; Camara, C. A.; Silva, T. M. S.; Martins, R. M.; Pinto, A. C.; Vargas, M. D.; Biorg. Med. Chem. Lett. 2005, 13, 6464.
  • 30
    Jacobsen, N.; Wengel, A.; Pestic. Sci. 1986, 17, 686.
  • 31
    Santos, A. F.; Ferraz, P. A. L.; Pinto, A. V.; Pinto, M. C. F. R.; Goulart, M. O. F.; Sant'Ana, A. E. G.; Int. J. Parasitol. 2000, 30, 1199.
  • 32
    Lima, N. M. F.; Santos, A. F.; Porfírio, Z.; Goulart, A. O. F.; Sant'Ana, A. E. G.; Acta Trop. 2002, 83, 43.
  • 33
    Carneiro, P. F.; Pinto, M. C. F. R.; Coelho, T. S.; Cavalcanti, B. C.; Pessoa, C.; de Simone, C. A.; Nunes, I. K. C.; de Oliveira, N. M.; de Almeida, R. G.; Pinto, A. V.; de Moura, K. C. G.; da Silva, P. A.; da Silva Jr., E. N.; Eur. J. Med. Chem 2011, 46, 4521.
  • 34
    Souza, N. B.; Andrade, I. M.; Carneiro, P. F.; Jardim, G. A. M.; Melo, I. M. M.; Silva, E. N.; Krettli, A. U.; Mem. Inst. Oswaldo Cruz 2014, 109, 546.
  • 35
    Guimarães, T. T.; Pinto, M. C. F. R.; Lanza, J. S.; Melo, M. N.; Monte-Neto, R. L.; Melo, I. M. M.; Diogo, E. B. T.; Ferreira, V. F.; Camara, C. A.; Valença, W. O.; Oliveira, R. N.; Frézard, F.; Silva Jr., E. N.; Eur. J. Med. Chem 2013, 63, 523.
  • 36
    Lima, N. M. F.; Correia, C. S.; Leon, L. L.; Machado, G. M. C.; Madeira, M. F.; Santana, A. E. G.; Goulart, M. O. F.; Mem. Inst. Oswaldo Cruz 2004, 99, 757.
  • 37
    Cushion, M. T.; Chen, F.; Kloepfer, N.; Antimicrob. Agents Chemother. 1997, 41, 379.

Publication Dates

  • Publication in this collection
    Jan 2019

History

  • Received
    14 Apr 2018
  • Accepted
    31 July 2018
Creative Common - by 4.0
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Sociedade Brasileira de Química Instituto de Química - UNICAMP, Caixa Postal 6154, 13083-970 Campinas SP - Brazil, Tel./FAX.: +55 19 3521-3151 - São Paulo - SP - Brazil
E-mail: office@jbcs.sbq.org.br
Acompanhe os números deste periódico no seu leitor de RSS